Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis

Expert Opinion on Pharmacotherapy
N M DaviesM A de Leeuw

Abstract

The discovery of the two isoenzymes of cyclooxygenase (COX) has recently lead to the development and clinical introduction of specific inhibitors of cyclooxygenase-2 (COX-2), such as celecoxib, onto the market. Celecoxib is an effective anti-inflammatory, analgesic and antipyretic agent therapeutically utilised in the management of osteoarthritis and rheumatoid arthritis. In addition, celecoxib has some novel therapeutic and pharmacological activities. Celecoxib inhibits anti-apoptotic kinase activation and is the first specific COX-2 inhibitor to be marketed for familial adenomatous polyposis, an inheritable predisposition for colorectal cancer. Celecoxib is not without gastrointestinal (GI) side effects but demonstrates markedly reduced GI ulceration in clinical trials when compared to traditional non-specific non-steroidal anti-inflammatory drugs (NSAIDs). The specific COX-2 inhibitors each have distinctive pharmacokinetic properties. Celecoxib can be given either once or twice daily. Racial differences in drug disposition, and pharmacokinetic changes in elderly patients, patients with chronic renal insufficiency and patients with mild to moderate hepatic impairment, are evident with celecoxib. Despite the specific action of...Continue Reading

References

Jul 1, 1990·Clinical Pharmacokinetics·R K Verbeeck
Oct 1, 1987·Annals of Internal Medicine·H J Kaufmann, H L Taubin
Jan 1, 1985·Pharmacotherapy·C A HellerP Goldman
Nov 1, 1996·The Journal of Clinical Investigation·B K ReuterJ L Wallace
Dec 1, 1996·Drugs & Aging·N M Davies, J L Wallace
May 23, 1997·Journal of Medicinal Chemistry·I K KhannaP C Isakson
Aug 26, 1998·British Journal of Rheumatology·M A IñiguezJ J Gomez-Reino
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·C J SmithP C Isakson
Jan 6, 1999·Proceedings of the National Academy of Sciences of the United States of America·B F McAdamG A FitzGerald
Jun 26, 1999·The New England Journal of Medicine·S Mohammed, D W Croom
Aug 3, 1999·Clinical Pharmacology and Therapeutics·J RossatM Burnier
Nov 7, 1999·Anesthesiology·S S Reuben, R Steinberg
Dec 2, 1999·JAMA : the Journal of the American Medical Association·L S SimonG S Geis
Dec 10, 1999·British Journal of Pharmacology·N MaricicB M Peskar
Jan 25, 2000·Clinical Therapeutics·R PattersonJ Lefkowith
Feb 17, 2000·Journal of the National Cancer Institute·K Smigel
Feb 22, 2000·Clinical Cornerstone·A H Soll, D McCarthy
Mar 1, 2000·Archives of Internal Medicine·R Carrillo-Jimenez, M Nurnberger
Mar 4, 2000·Biopharmaceutics & Drug Disposition·S K PaulsonA Karim
Mar 31, 2000·European Journal of Gastroenterology & Hepatology·F KarmeliD Rachmilewitz
Apr 15, 2000·Annals of Internal Medicine·A M BaciewiczT J King
Apr 25, 2000·Annual Review of Medicine·J A Baron, R S Sandler
May 29, 2000·Archives of Internal Medicine·A WheltonG S Geis
Jun 1, 2000·The American Journal of Psychiatry·M S Lantz, V Giambanco
Jun 10, 2000·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Y TakahashiR I Clyman

❮ Previous
Next ❯

Citations

Mar 17, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Swati Rawat, Sanjay K Jain
Dec 2, 2004·Journal of the National Cancer Institute·Xiangguo LiuShi-Yong Sun
Oct 10, 2006·AAPS PharmSciTech·Kora Pattabhi Ramaiah Chowdary, Sekuboyina Vijaya Srinivas
Jun 29, 2011·Drug Development and Industrial Pharmacy·Ehab A FouadIbrahim A Alsarra
Feb 5, 2002·Expert Opinion on Pharmacotherapy·A Bennett, I A Tavares
Apr 23, 2004·Journal of Clinical Pharmacology·Honghui ZhouJoan Korth-Bradley
Sep 16, 2003·Journal of Clinical Pharmacology·Thorir D BjornssonCaroline Loew
Sep 1, 2006·AAPS PharmSciTech·Kora Pattabhi Ramaiah Chowdary, Sekuboyina Vijaya Srinivas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenomatous Polyposis Coli

Adenomatous polyposis coli is a protein encoded by the APC gene and acts as a tumor suppressor. Discover the latest research on adenomatous polyposis coli here.